Teva's Losartan Potassium Supplement Application Receives Standard Review Status
Teva's ANDA for Losartan Potassium has been submitted and is currently under standard review by the FDA.
Published: August 6, 2026
Updated: August 6, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Antihypertensive
Company: Teva
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Teva
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Teva's submission for Losartan Potassium under standard review by the FDA signals a potential shift in the competitive landscape of the antihypertensive market. This could lead to changes in pricing and availability, impacting market dynamics significantly.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include the FDA's decision on the application and any subsequent market entry timelines.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.